Drug Profile
INF 101
Alternative Names: INF-101; OX-1001Latest Information Update: 13 Sep 2023
Price :
$50
*
At a glance
- Originator OncoNOX
- Developer Inflamalps
- Class
- Mechanism of Action Peptide hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Dry eyes
- Discontinued Uveitis
Most Recent Events
- 13 Sep 2023 INF 101 is still in preclinical development in Dry-eyes in Switzerland (Topical) (Inflamalps pipeline, September 2023)
- 13 Sep 2023 Discontinued - Preclinical for Uveitis in Switzerland (Topical) (Inflamalps pipeline, September 2023)
- 13 Sep 2023 Inflamalps plans phase I trial in Dry eyes (Inflamalps pipeline, September 2023)